Clinical Trial Update: Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

View source ↗

Summary

Real-world clinical trial update on sacituzumab govitecan as monotherapy or in combination for recurrent or metastatic HER2-negative breast cancer; the study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hr-positive Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Sacituzumab Govitecan (Trodelvy) (sacituzumab govitecan)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Breast Neoplasms, Triple Negative Breast Cancer | Status: ACTIVE_NOT_RECRUITING